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Running title: A TAT-SPK2 peptide protects against cerebral ischemia/reperfusion 
Abstract 
We have previously shown that sphingosine kinase 2 (SPK2) interacts with Bcl-2 via 
its BH3 domain, activating autophagy by inducing the dissociation of Beclin-1/Bcl-2 
complexes, and that a TAT-SPK2 peptide containing the BH3 domain of SPK2 protects 
neurons against ischemic injury. The goals of the present study were to establish the 
functional significance of these findings, by testing whether TAT-SPK2 was effective 
in a mouse model of ischemic stroke, and to explore potential underlying mechanisms. 
Mice were administered with TAT-SPK2 by intraperitoneal injection before or after 
transient middle cerebral artery occlusion (tMCAO). Infarct volume, neurological 
deficit and brain water content were assessed 24 h after reperfusion. Mitophagy 
inhibitor Mdivi-1 and BNIP3 siRNAs were used to examine the involvement of BNIP3-
dependent mitophagy in the neuroprotection of TAT-SPK2. Mitophagy was quantified 
by immunoblotting, immunofluorescence and electron microscopy. The interaction 
between TAT-SPK2 and Bcl-2, Bcl-2 and BNIP3 was detected by co-
immunoprecipitation. In the tMCAO model, pre-treatment with TAT-SPK2 
significantly reduced infarct volume, improved neurological function and decreased 
brain edema. Neuroprotection by TAT-SPK2 was still seen when the peptide was 
administered 3 h after reperfusion. TAT-SPK2 also significantly improved functional 
recovery and reduced long-term brain atrophy of the ischemic hemisphere 30 days after 
administration. Our studies further showed that TAT-SPK2 directly binds to Bcl-2 and 
disrupts Bcl-2/Beclin-1 or Bcl-2/BNIP3 complexes to induce mitophagy. These results 
suggest that TAT-SPK2 protects neurons against ischemia reperfusion injury by 
activating BNIP3-mediated mitophagy. Agents exploiting this molecular mechanism 
are potential candidates for the treatment of ischemic stroke. 







Stroke, due to a sudden loss of blood flow to a region of the brain, is one of the main 
causes of death worldwide. Ischemic strokes represent 80% of all strokes, and are 
associated with high mortality, morbidity and recurrence (Feigin et al., 2017). 
Intravenous recombinant tissue plasminogen activator (tPA) is still the only specific 
pharmacological treatment for ischemic stroke, but narrow treatment window and risk 
of hemorrhagic transformation limit its use (Pena et al., 2017). Thus, it is of great 
urgency to develop novel therapeutic drugs for ischemic stroke. 
Sphingolipids, one of the largest classes of bioactive lipids, are implicated in cell 
structure, metabolism and signal transduction (Bartke and Hannun, 2009). Among 
them, sphingosine 1- phosphate (S1P), produced by the action of sphingosine kinases 
(SPK1 and SPK2), regulates the proliferation, survival and migration of neurons in the 
central nervous system (Blondeau et al., 2007; Harada et al., 2004; Song et al., 2018). 
Previous work from our laboratory established that isoflurane- or hypoxic 
preconditioning upregulated SPK2 and activated autophagy (Sheng et al., 2014b; Yung 
et al., 2012). The interaction of SPK2’s BH3 domains with Bcl-2 might mediate 
autophagy activation and ischemic tolerance by inducing the dissociation of Bcl-2/ 
Beclin-1 complexes., we thus designed a TAT-SPK2 peptide containing the BH3 
domain of SPK2 and found that it protected neurons against oxygen glucose 
deprivation-induced cell death (Song et al., 2017). 
The aim of this study was to determine whether TAT-SPK2 is effective in vivo in an 
animal model of ischemic stroke and therefore shows clinical value. We also chose to 
focus on BCL-2/adenovirus E1B 19 kDa interacting protein 3 (BNIP3) to explore its 
possible underlying mechanisms. BNIP3 is primarily localized on the mitochondrial 
outer membrane where it plays an important role in mitochondrial dynamics (Zhang 
and Ney, 2009) and mitophagy (i.e., the selective removal of mitochondria by 
autophagy (Ashrafi and Schwarz, 2013; Youle and Narendra, 2011)). BNIP3 is a BH3 
only protein that mediates hypoxia-induced mitophagy by disrupting the interaction of 
Beclin-1 with Bcl-2(Bellot et al., 2009), similar to the mechanism of SPK2 mediated 
autophagy. Since hypoxia-induced mitophagy via BNIP3 and BNIP3L is known to 
underpin survival mechanisms, we thus intend to test the hypothesis that TAT-SPK2 
mediates neuroprotection via activation of BNIP3-mediated mitophagy by interacting 





Materials and Methods.  
In vivo experimental design 
ICR mice (male, 8-10 weeks old, 25–30 g) were acquired from the Center of 
Experimental Animals of Soochow University. Animals were kept in an environment 
with a 12 h light/dark cycle, with free access to food and water and controlled 
temperature (20-25°C) and humidity (40-70%). The Chinese national guidelines for 
laboratory animal care and use were followed in all animal experiments. Care and 
handling of animals were approved by the Ethical Committee of Soochow University. 
The mice were randomly allocated to different groups for short-term study and long-
term study (Figure S1A). In short-term study, the peptide entry, efficacy, time window 
and mitophagy assay of TAT-SPK2 were studied. In the long-term study, the ischemic 
atrophy and neurological function were investigated. The animals that showed overly 
deteriorated conditions after transient middle cerebral artery occlusion (tMCAO) 
surgery, such as inability to move, loss of consciousness, etc. were humanely 
euthanized. The mice were excluded from the analysis if death occurred during surgery 
or within 24 hours, or if the model failed for technical reasons (blood flow during 
MCAO did not decrease by 90% or did not return to 85-95% of baseline during 
reperfusion). The final number of mice included in the analysis is the total number 
minus the excluded number (Table S1). 
Transient middle cerebral artery occlusion model in mice 
Mice were anaesthetized with 1.5% (v./v.) isoflurane in air by an animal anaesthesia 
ventilator system. The transient middle cerebral artery occlusion (tMCAO) model in 
mice was implemented as described previously, using a silicone-coated nylon (6-0) 
monofilament (Doccol Corporation 602356PK5Re) to occlude the right MCA (Li et al., 
2016). Mice were placed on a heating blanket to keep the body temperature at 37.0 ± 
0.5 °C. After 2 hours of occlusion, the filament was pulled out to restore cerebral blood 
flow. Blood flow reduction and recovery were documented using a laser Doppler blood 
flow meter (LDF ML191). Further experiments were only carried out in mice whose 
blood flow was reduced by 90% during MCAO and recovered to 85-95% of baseline 
during reperfusion. After surgery, the mice were placed in an incubator until they were 
fully awake and active, and were placed back into cages in an environment with fewer 
than five mice in each cage. 
Twenty-four hours after reperfusion, the neurological scores were measured by an 




After scoring, the mice were euthanized by decapitation under anesthesia. Brains were 
quickly removed. Then the infarct volume was evaluated using 2,3,5-
triphenyltetrazolium chloride (TTC) staining. The brain water content was also 
examined as described (Huang et al., 2018; Li et al., 2016). The detailed methods are 
shown in the supplemental methods. 
Behavioral tests and evaluation of atrophy volume 
A series of behavioral tests including beam balance test and rotarod test was conducted 
in a separate cohort of mice at fourteen and twenty-eight days after cerebral ischemia 
by two investigators blinded to the experimental grouping (Huang et al., 2018) (Li et 
al., 2016). The detailed methods are shown in the supplemental methods. 
Ipsilateral brain atrophy was used as a measure of long-term stroke-induced structural 
damage. Mice were euthanized after behavioral testing and perfused with PBS followed 
by 4% paraformaldehyde. Brains were photographed before being cut into five 2mm-
thick slices; images of these slices were acquired with a scanner. The brain atrophy area 
in each slice was quantified using Image J (Schneider et al., 2012) and calculated using 
the formula: atrophy volume = (area of contralateral side – area of ipsilateral side) / 
whole contralateral hemisphere area ×100%. 
Electron microscopy 
Six hours after drug administration, adult male ICR mice weighing 25–30 g were 
sacrificed and perfused with PBS followed by 2.5% glutaraldehyde. The parietal cortex 
was dissected, post-fixed with 2.5% glutaraldehyde overnight, incubated in 1% osmium 
tetroxide, dehydrated in acetone and embedded in epoxy resin. Blocks were sectioned 
on an ultramicrotome (100 nm), stained with uranyl acetate and lead citrate, and 
observed under an electron microscope (JEOL JEM-1230) (Sheng et al., 2010). At least 
15 cortical neurons were randomly selected from each sample to observe the double-
membrane vacuole structures or vacuole structures engulfing mitochondria and 
partially degraded mitochondria (Sheng et al., 2014a).  
Toxicology assessment 
In the acute toxicity study, normal mice were administered intraperitoneally with a 
single dose of 80 mg/kg TAT-SPK2 (20 times the highest therapeutic dose) or TAT-
L219A, and were monitored for 7 days. In the subacute toxicity study, normal mice 
received vehicle or TAT-SPK2 (4 mg/kg/day, intraperitoneal injection) for 2 weeks 
(Shen et al., 2015). The detailed methods are shown in the supplemental methods. 




The experimental design of the in vitro studies is summarized in Figure S1B. Mouse 
hippocampal neuronal HT22 cells (Shanghai Institute of Cell Biology) were cultured 
in Dulbecco’s modified Eagle’s medium (DMEM, Gibco) supplemented with 10% fetal 
bovine serum (FBS, Gibco), 100 U/ml penicillin, 100 U/ml streptomycin at 37°C in 5% 
CO2/95% air. The oxygen-glucose deprivation and reoxygenation (OGD/R) were 
performed as described previously (Cao et al., 2007). HT22 cells were incubated with 
HEPES balanced salt solution (HBSS: NaCl 140 mM, KCl 3.5 mM, MgSO4 12 mM, 
CaCl2 1.7 mM, NaHCO3 5 mM, KH2PO4 0.4 mM, HEPES 10 mM; pH 7.2-7.4) and 
placed in a chamber (Billups-Rothenberg MC-101) filled with 95% N2 / 5% CO2 at 
37 °C. Six hours later, the HBSS was replaced with complete medium and the cells 
were cultured under normal condition (Sheng et al., 2012).  
Cell viability assay 
Cell viability was assessed using Cell Counting Kit-8 (CCK-8, Dojindo Laboratories). 
Cells were cultured in 96-well plates at a density of 1×105 cells/ well. Each well was 
incubated with 10μl CCK-8 medium for 2 h at 37°C. The optical density at 450 nm was 
measured using a plate reader (ELX 800, Bio-Tek).  
Drug treatment 
The TAT-SPK2 peptide (YGRKKRRQRRRGGSGDGLLYEVLNGLLDRPD) and its 
negative control TAT-L219A (YGRKKRRQRRRGGSGDGLLYEVANGLLDRPD) 
were synthesized by Chinese Peptide Company (purity 95%, Hangzhou, China) as 
previously described (Song et al., 2017).  
For in vivo studies, TAT-SPK2 (1-4 mg/kg), TAT-L219A (4 mg/kg) or edaravone (3 
mg/kg, positive neuroprotective control; China National Medicines Guorui 
Pharmaceutical Co. Ltd., Huainan, China) were dissolved in 0.9% normal saline and 
administered intraperitoneally (1ml/100g body weight) 1h before ischemia or at the 
indicated time after reperfusion. Mice were administered intraperitoneally with 8.5 
μM/kg mitochondrial division inhibitor-1 (Mdivi-1,Tocris Cookson Ltd., Bristol, UK) 
at the beginning of reperfusion (Shen et al., 2017). Mdivi-1 was first dissolved in 
DMSO to prepare a 100 mM stock solution, and then diluted with normal saline to a 
final concentration of 0.85 mM (1 ml/100g body weight, the final DMSO 
concentration=0.84%). Control mice were treated with the same volume of vehicle. 
For in vitro studies, TAT-SPK2 or TAT-L219A were dissolved in double-distilled 
water and then diluted as needed using complete medium. HT22 cells were incubated 




incubated with the peptides 1 h before and during OGD. Cells were then treated with 
25 μM Mdivi-1 (the final DMSO concentration=0.025%) for 12 h following OGD. 
Control cells were treated with the same volume of vehicle. 
siRNA 
Small interfering RNAs specific to BNIP3 (siRNA 1, sense: 5'-GGACGAA-
GUAGCUCCAAGATT-3', antisense: 5'-UCUUGGAGCUACUUCGUCCTT-3’; 
siRNA 2, sense: 5'-GAAGAGAAGUUGAAAGUAUTT-3', antisense: 5'-AUACU-
UUCAACUUCUCUUCTT-3') and a non-silencing control siRNA (negative control, 
NC) were synthesized by Genepharma (Shanghai, China). BNIP3 siRNAs (40 nM) 
were transfected into HT22 cells using lipofectamine 2000 (Invitrogen). The efficacy 
of BNIP3 knockdown was assessed using Western blotting (Zhang et al., 2015). 
Western blot analysis 
The ipsilateral cortex, striatum and hippocampus were dissected out, homogenized and 
lysed with a buffer containing 150 mM NaCl, 10 mM Tris-HCl, pH 7.4, 1% sodium 
deoxycholate, 1% Triton X-100, 5mM EDTA, 10% SDS and 2% Protease Inhibitor 
Cocktail Tablets (Roche, 04693132001). Cells were washed twice with ice cold PBS 
and lysed in the same buffer. An aliquot of 30–50 μg protein from each sample was 
separated with SDS-PAGE and transferred to a nitrocellulose membrane, which was 
then incubated with 5% non-fat milk for 1 h. The levels of Bcl-2 (1:100; Santa Cruz sc-
7382; RRID: AB_626736), Beclin-1 (1:1000, Santa Cruz sc-11427; RRID: 
AB_2064465), BNIP3 (1:1000; Cell Signaling Technology CST3769; RRID: 
AB_2259284), P62 (1:1000; Cell Signaling Technology CST5114S; RRID: 
AB_10624872), LC3 (1:1000; NOVUS NB600-1384; RRID: AB_669581), DRP1 
(1:1000; Santa Cruz sc-101270), Parkin (1:1000; Cell Signaling Technology 
CST4211S), Tom20 (1:500; Proteintech 11802-1-AP) and α-tubulin (1:10000, Sigma-
Aldrich T6074) was measured with Western blotting. The membranes were incubated 
with secondary antibodies (1:20000; LI-COR Biosciences, IRDye 800CW Donkey 
anti-Mouse 926–32212; RRID: AB_621847; IRDye 800CW Donkey anti-Rabbit 926–
32213; RRID: AB_621848) and visualized by the Odyssey infrared imaging system 
(LI-COR Bioscience). The blots were analyzed using Image J, using β-actin (1:10000; 
Sigma A5441; RRID: AB_476744) to normalize for loading differences.  
Immunofluorescence 
Cells were fixed with 4% paraformaldehyde for 15min and incubated with 0.1% Triton 




primary antibodies against LC3 (1:500; NOVUS NB600-1384) and COXIV (1:500; 
CST 11967) at 4°C overnight. Then cells were incubated with anti-mouse IgG (H+L) 
secondary antibody, DyLight 488 (1:500; Invitrogen) and anti-rabbit IgG secondary 
antibody, Dylight 594 (1:1000; Invitrogen) for 3 h. Nuclei were counterstained with 
DAPI (1:10000; Sigma D9564) for 15 min. Fluorescence images were captured using 
a laser confocal microscope (ZEISS LSM710). At least 30 cells were randomly selected 
and observed in each group, and then the overlap coefficient was analyzed using Image 
J. The immunofluorescence was performed in three independent cultures. 
Mitochondria isolation 
Mitochondrial and cytoplasmic fractions were extracted using a commercial 
mitochondria isolation kit (Beyotime, C3606). Briefly, 50-100 mg of cortex were 
resuspended with ten volumes of solution A and then homogenized with a Kimble glass 
homogenizer on ice. The homogenate was centrifuged at 600 g for 5 min and then the 
resulting supernatant was further centrifuged at 11000 g for 10 min. The final 
supernatant and precipitation were cytoplasm and mitochondria respectively.  
Mitochondrial function assay 
The intracellular ATP level was measured using a commercial ATP assay kit (Beyotime, 
S0026) according to the manufacturer’s protocol. Tetramethylrhodamine (TMRM) was 
a kind of cell-permeable dye used for analyzing mitochondrial membrane potential 
dynamics of living cells (Lampert et al., 2019; Li et al., 2018). Live cells were incubated 
with 100nM TMRM (Invitrogen I34361, 100nM) and Hoechst 33258 (Invitrogen 
H3569, 1μg/ml) for 30 min at 37°C. Images were captured using a fluorescence 
microscope system (Olympus IX73) and fluorescence intensity was quantified using 
Image J software. 
Co-immunoprecipitation  
The N-terminals of TAT-SPK2 and TAT-L219A were conjugated to biotin (Chinese 
Peptide Company, purity 95%). Approximately 1×107 cells were treated with 
biotinylated peptides (10 μM, 1h) and lysed in a buffer (150 mM NaCl, 50mM Tris-
HCl, pH 7.4, 0.05% sodium deoxycholate, 1% NP40 and 2% Protease Inhibitor 
Cocktail Tablets). Then the protein concentration of each group was quantified with 
BCA assay. One milligram of protein from each group was incubated with M-280 
streptavidin Dynabeads (Invitrogen, 11205D). The immunoprecipitates were separated 
with SDS-PAGE and then measured using anti-Bcl-2 antibody (Santa Cruz sc-7382) 




To examine the effect of TAT-SPK2 on the interaction between Bcl-2 and Beclin-1or 
BNIP3, cells were lysed in the buffer described above. The lysates were precleaned 
with protein A/G magnetic beads (Bimake, B23202) for 1h, and then incubated with 
antibody against Bcl-2 (Santa Cruz sc-7382) or IgG (normal mouse IgG, Santa Cruz 
sc-2025) overnight. Lysates were mixed with protein A/G magnetic beads for 6h after 
eluting the unbound antibody. The immunoprecipitates were separated by SDS-PAGE.  
Beclin-1 (Santa Cruz sc-11427) or BNIP3 (CST CST3769) was examined using 
Western blotting. 
Statistical analysis  
Data are expressed as mean ± SD unless noted otherwise. Differences between two 
groups were determined with unpaired two-tailed Student's t-test, while one-way or 
two-way repeated ANOVA was used to analyze more than two groups. When 
significant, omnibus tests were followed by Newman-Keuls test or Bonferroni test as 
post-hoc analysis. Post-hoc analysis was run only if there was no significant variance 
inhomogeneity. Neurological deficit score was compared using non-parametric 
statistics (Kruskal-Wallis test) and Dunn’s test was used for post-hoc analysis. In all 
analyses, P values of < 0.05 were considered statistically significant. 
 
Results 
TAT-SPK2 peptide reduced ischemic injury in mouse tMCAO model. 
Our previous finding showed that a TAT-SPK2 peptide designed from the BH3 domain 
of SPK2 protected primary neurons and HT22 neuronal cells against OGD/R injury 
(Song et al., 2017).  Our goal was now to test the hypothesis that TAT-SPK2 is effective 
in vivo, in particular in an animal model of ischemic stroke. By imaging the brain tissue 
with Alexa Fluor 488-streptavidin conjugate, we demonstrated that biotin-TAT-SPK2 
penetrates the blood brain barrier and enters the brain 6h after intraperitoneal injection 
(Figure S2). We next examined the efficacy of TAT-SPK2 in a mouse tMCAO model. 
To assess specificity, the effect of a TAT-L219A peptide composed of the BH3 domain 
of L219A-mutated SPK2 was also examined as a negative control (Song et al., 2017). 
We chose edaravone (Lei et al., 2014; Shichinohe et al., 2004) as a positive control 
because this small-molecular weight reactive oxygen scavenger is approved for the 
specific management of ischemic stroke in Japan (Jin et al., 2017). Many animal studies 
also use edaravone as a positive drug for the treatment of ischemic stroke (Wu et al., 




was based on literatures (Shichinohe et al., 2004; Zhang et al., 2005). The dose of TAT-
SPK2 in cerebral ischemia model was determined based on preliminary experiments. 
Our preliminary results showed that 2mg/kg and 4mg/kg of TAT-SPK2 intraperitoneal 
administration could effectively reduce the infarct volume in a mouse tMCAO model 
(data not shown). We thus set the dose of TAT-SPK2 as 1, 2, 4mg/kg. Mice were 
intraperitoneally administered with TAT-SPK2 (1, 2, 4 mg/kg), TAT-L219A (4 mg/kg) 
or edaravone (3 mg/kg) 1 h before the ischemia. The neurological deficit and brain 
infarct volume were assessed 24h after reperfusion. TAT-SPK2 (1, 2 and 4 mg/kg) dose-
dependently reduced the infarct volume from 57.9% ± 3.7% in the tMCAO+vehicle 
group, to 49.7% ± 7.2%, 41.9% ± 11.2% and 34.2% ± 8.3% respectively, while TAT-
L219A failed to show any protection (55.1% ± 7.0%). TAT-SPK2 caused the largest 
reduction in infarct volume at 4 mg/kg and this effect was similar to that of 3 mg/kg 
edaravone (Figure 1A). TAT-SPK2 also restored the neurological deficit at 4mg/kg 
(Figure 1B) and decreased the brain water content at 1 - 4mg/kg (Figure 1C), consistent 
with the effects on infarct volume.  
To establish a more clinically relevant therapeutic window, TAT-SPK2 (4 mg/kg) was 
intraperitoneally administered at reperfusion, or 1, 2, 3 or 4 h thereafter. With infarct 
volume at 24 hours as an outcome measure, TAT-SPK2 was effective when 
administered up to 3 hours after reperfusion (Figure 2A). However, a significant effect 
on neurological deficits was only observed when TAT-SPK2 was administered at 
reperfusion or 1 hour after reperfusion (Figure 2B). Interestingly, a significant effect of 
TAT-SPK2 on brain water content was seen at all administration time points, including 
4 hours after reperfusion (Figure 2C), likely due to the lower variability of this outcome 
measure.  Taken together, these results indicate that TAT-SPK2 could be 
neuroprotective after transient ischemic stroke when administered up to 3 hours after 
reperfusion.  
To confirm that the neuroprotective effects of 4 mg/kg TAT-SPK2 (administered at 
reperfusion) extended beyond 24 hours, we investigated its long-term effects in mice 
subjected to ischemia/reperfusion injury (Huang et al., 2018; Qin et al., 2017).  We 
assessed the behavioral recovery 14 and 28 days after tMCAO. At 14 days after 
tMCAO, the mice showed obvious neurological deficit. Compared with the sham 
group, the mice passed the balance beam with a longer time (Figure 3B) and fell off the 
rotarod easily (Figure 3C). The neurological behavior of mice recovered at 28 days 




be due to the severity of the tMCAO model and behavioral evaluation system in this 
study (Huang et al., 2018; Li et al., 2016; Qin et al., 2017) . At both 14 and 28 days 
after tMCAO, TAT-SPK2 shortened the time to get through the balance beam (Figure 
3B) and extended the time to fall off the rotarod (Figure 3C) compared to vehicle-
treated mice. The shrinkage/atrophy of the ischemic hemisphere was assessed 30 days 
after ischemia/reperfusion. Compared to vehicle-treated mice, TAT-SPK2 markedly 
decreased the atrophy volume from 49.6% ± 6.9% to 26.5% ± 6.3% (Figure 3A).  These 
data suggested the TAT-SPK2-mediated reduction of ischemic hemisphere atrophy was 
accompanied with long-term functional recovery in mouse tMCAO model. 
We conducted a preliminary toxicological evaluation of the TAT-SPK2 peptide. None 
of the 12 normal mice administered intraperitoneally with a single dose of 80 mg/kg 
TAT-SPK2 (20 times the highest therapeutic dose) or TAT-L219A (6 mice per group) 
died within 7 days. The body weight (Figure S3A), food and water intake, breathing, 
excretion, and behavior of the mice did not change significantly during one week of 
follow-up. There was no significant difference among TAT-SPK2, TAT-L219A and 
control group in the levels of blood biomarkers reflecting organ toxicity including 
creatinine (Figure S3B) for kidney, glutamic pyruvic transaminase (GPT, alanine 
aminotransferase, ALT, Figure S3C) and glutamic oxalacetic transaminase (GOT, 
aspartate aminotransferase, AST, Figure S3D) for liver, and lactate dehydrogenase 1 
(LDH1, Figure S3E) for heart damage. HE-staining of organs including heart, lung 
liver, kidney, spleen and testis also showed no obvious histopathological changes 
(Figure S3F). These results in a small cohort of mice suggest that a single 20 times the 
highest therapeutic dose of TAT-SPK2 peptide displayed no overt organ toxicity in 
mice.  
We also performed a long-term chronic safety evaluation with TAT-SPK2 at 
therapeutic dose (4 mg/kg). Daily 4 mg/kg TAT-SPK2 was well tolerated in adult mice 
during a two-week treatment (6 mice per group). During the period of observation, there 
were no visual difference between mice in terms of feeding and water intake, breathing, 
excretion and daily behavior (Data not shown). Compared with vehicle controls, mice 
had normal weight gain (Figure 4A) and organ weight indices of liver, spleen and 
kidney (Figure 4B-D). There was also no statistical difference between TAT-SPK2 and 
control in the levels of blood biomarkers including creatinine (Figure 4E), ALT (Figure 
4F), AST (Figure 4G) and LDH1 (Figure 4H). No observable histopathological changes 




either (Figure 4I). These results further suggest that daily 4 mg/kg TAT-SPK2 peptide 
during a two-week treatment displayed no overt organ toxicity in mice.  
TAT-SPK2 peptide induced mitophagy in vivo and in vitro 
To investigate whether autophagy or mitophagy underlies TAT-SPK2-mediated 
protection against ischemia/reperfusion, we assessed the autophagic markers LC3 and 
P62 in cortex, hippocampus and striatum 1, 3, 6, 12 and 24 h after TAT-peptide 
administration to control mice. TAT-SPK2 (T-S), but not TAT-L219A (T-L) 
significantly upregulated LC3II/β-actin ratio in cortex (Figure 5A) and hippocampus 
(Figure S2A) after 6 h treatment, whereas LC3II/β-actin was markedly increased in 
striatum from 6 h-24 h (Figure S4A). P62 was significantly down-regulated in the three 
brain regions at 6 h (Figure 5B, Figure S4B) of TAT-SPK2 treatment.  
We then used electron microscopy to evaluate autophagosome formation in cortical 
neurons. In the cortical neurons of mice treated with vehicle or TAT-L219A, the 
organelles and nuclei seemed normal and healthy. The mitochondria had complete and 
clear double membrane and crista structures. Six hours after TAT-SPK2 treatment, the 
organelles and nuclei in neurons also appeared normal without significant damage, but 
increased number of double-membrane structures containing mitochondria and 
partially degraded mitochondria was found in TAT-SPK2 group compared with control 
or TAT-L219A group, suggesting possible mitophagy induction after TAT-SPK2 
treatment (Figure 5D). The mitochondrial recruitment of DRP1, PINK1/Parkin is 
crucial for mediating mitophagy activation (Chen and Dorn, 2013; Feng et al., 2018a; 
Rana et al., 2017). We thus investigated the distribution of DRP1, Parkin and P62 in 
the mitochondrial and cytoplasmic fractions of mouse cortex after TAT-SPK2 
treatment. The results showed that six hours after the administration of TAT-SPK2, 
compared with the vehicle or TAT-L219A treatment group, more DRP1 and Parkin 
were recruited in the mitochondria, accompanied by more degradation of mitochondrial 
P62 (Figure 5E). These data further support the activation of mitophagy by TAT-SPK2. 
Our previous work established that one-hour treatment with TAT-SPK2, but not with 
TAT-L219A, could activate autophagy in HT22 neuronal cells (Song et al., 2017). In 
the present study, we further evaluated mitophagy in HT22 cells 1 h after TAT-SPK2 
administration using double-staining immunofluorescence microscopy. Mitochondria 
and autophagosomes were visualized with mitochondrial marker COXIV and with 
LC3, respectively. TAT-SPK2 increased the overlap between COXIV-stained 




and TAT-L219A groups (Figure 5F), supporting the notion that TAT-SPK2 
administration was associated with increased mitophagy. Taken together, our data 
indicate that TAT-SPK2 peptide activates mitophagy both in vivo and in vitro. 
Inhibition of mitophagy blocks the neuroprotection of TAT-SPK2 peptide  
To elucidate the role of mitophagy in TAT-SPK2-mediated neuroprotection, we tested 
the effects of a mitophagy inhibitor in in vitro and in vivo models of cerebral 
ischemia/reperfusion. Mdivi-1 is a specific inhibitor of dynamin-related protein 1 
(DRP1), a mitochondrial fission protein (Tanaka and Youle, 2008) used in many recent 
studies as an inhibitor of mitophagy (Cassidy-Stone et al., 2008; Mizumura et al., 2014; 
Pi et al., 2013; Zhang et al., 2013). Mitophagy usually target small and round 
mitochondria. When Mdivi-1 inhibits mitochondrial fission, the mitochondria that have 
not undergone fission cannot be engulfed by phagophores, the precursors to 
autophagosomes; hence, Mdivi-1 can indirectly inhibit mitophagy.  
HT22 cells were incubated with TAT-SPK2 or TAT-L219A for 1 h. Cells were then 
subjected to 6 h of OGD and exposed to Mdivi-1 immediately after re-oxygenation. As 
shown in the results, Mdivi-1 significantly reduced the protective effect of TAT-SPK2 
(Figure 6A). 
Similar results were obtained in vivo. Mice were administered with 4 mg/kg TAT-
SPK2 at the onset of ischemia, and then subjected to tMCAO. Mdivi-1 (3 mg/kg), 
administered intraperitoneally at the onset of reperfusion, partially abolished the 
neuroprotective effects of TAT-SPK2, which was reflected in the increased infarct 
volumes and worse neurological scores (Figure 6B-D). Overall, these data offer support 
for the hypothesis that mitophagy is involved in TAT-SPK2-mediated neuroprotection 
against cerebral ischemia. 
BNIP3 is involved in the neuroprotection conferred by TAT-SPK2 peptide  
BNIP3 plays a key role in hypoxia-induced mitophagy (Bellot et al., 2009). BNIP3 
binds to LC3 on the autophagosome and induces autophagic clearance of both 
endoplasmic reticulum (“ER-phagy”) and mitochondria (mitophagy) (Hanna et al., 
2012). However, it is unclear whether BNIP3 is required for TAT-SPK2-mediated 
mitophagy. Our in vivo studies showed that TAT-SPK2 treatment significantly 
increased BNIP3 protein levels at 6 h in the cortex (Figure 5C), striatum and 
hippocampus (Figure S5). Consistently, in HT22 cell cultures, BNIP3 protein levels 
increased 1-6 h after treatment with TAT-SPK2 compared with the control or TAT-




We next investigated whether BNIP3 contributes to TAT-SPK2-induced mitophagy 
and neuroprotection. BNIP3 was knocked down by two siRNAs, which efficiently 
reduced BNIP3 expression in HT22 cells compared to the negative control (Figure 7B). 
Notably, both BNIP3 siRNAs significantly reversed TAT-SPK2-induced overlap 
between COXIV and LC3 labeling (Figure 7C), indicating that BNIP3 is required for 
TAT-SPK2-induced mitophagy activation. In addition, knockdown of BNIP3 
effectively abolished TAT-SPK2-mediated protection (Figure 7D). Role of 
autophagy/mitophagy activation in ischemic stroke is controversial (Feng et al., 2017). 
Moderate mitophagy may help to maintain mitochondrial function, while excess 
mitophagy may lead to mitochondrial dysfunction (Ashrafi and Schwarz, 2013; 
Palikaras et al., 2018). To further investigate the effect of TAT-SPK2-mediated 
mitophagy on mitochondrial function, we evaluated mitochondrial function by 
assessing ATP level and mitochondrial membrane potential. The results showed that 
ATP level (Figure 7E) and mitochondrial membrane potential assessed by TMRM 
staining (Figure 7F) were significantly reduced in neuronal cells treated with OGD/R, 
while TAT-SPK2 resumed the ATP level and mitochondrial membrane potential 
compared to OGD/R group. Importantly, BNIP3 knockdown eliminated the protective 
effect of TAT-SPK2 on mitochondrial function, indicating that TAT-SPK2 may help to 
restore mitochondrial function via BNIP3-mediated mitophagy. Overall, these data 
suggest that BNIP3-dependent mitophagy is involved in TAT-SPK2-induced 
neuroprotection against cerebral ischemia. 
TAT-SPK2 peptide interacts with Bcl-2 and disrupts the BNIP3/Bcl-2 and Beclin-
1/Bcl-2 complex   
We have previously shown that SPK2 interacts with Bcl-2 via its BH3 domain to induce 
the dissociation of Beclin-1/Bcl-2 complexes (Song et al., 2017). We thus performed 
biochemical analyses with biotin-conjugated TAT-SPK2 to test the hypothesis that our 
TAT-SPK2 peptide, designed based on the BH3 domain of SPK2, interacts with Bcl-2 
as well. Endogenous Bcl-2 immunoprecipitated with the biotin-TAT-SPK2 but not with 
biotin-TAT-L219A (Figure 8A). As expected, TAT-SPK2 treatment markedly 
decreased the co-immunoprecipitation of Beclin1/Bcl-2 (Figure 8B-C). BNIP3 is 
known to interact with Bcl-2 directly via its BH3 domain to regulate mitophagy (Bellot 
et al., 2009; Maiuri et al., 2007; Mazure and Pouyssegur, 2009; Song et al., 2017; Zhang 
et al., 2008) . We thus further tested the co-immunoprecipitation of BNIP3 and Bcl-2 




BNIP3 co-immunoprecipitated with Bcl-2 compared with TAT-L219A and the control 
(Figure 8D-E). Overall, these findings confirm that TAT-SPK2 interacts with Bcl-2 to 
induce the dissociation of BNIP3/Bcl-2 or Beclin-1/Bcl-2 complexes. 
 
Discussion 
SPK2 seems to play a role in cerebral preconditioning, but the cell types and 
mechanisms underlying this effect has not been fully characterized (Song et al., 2018; 
Wacker et al., 2012; Wacker et al., 2009; Yung et al., 2012). An SPK2-dependent 
mechanism is also involved in the neuroprotection against cerebral ischemia 
(Pfeilschifter et al., 2011). Our previous finding showed that isoflurane- or hypoxia-
induced preconditioning could increase SPK2 expression to activate autophagy and 
mediate ischemic tolerance (Sheng et al., 2014b). SPK2 activates autophagy by 
dissociating Bcl-2/ Beclin-1 complex via interaction with the BH3 domain of Bcl-2. 
Accordingly, we designed an SPK2-derived TAT-peptide  containing the BH3 domain 
of SPK2 (TAT-SPK2) (Song et al., 2017). In the present study, we sought to investigate 
whether TAT-SPK2 is effective in a mouse model of ischemic stroke. We found that 
TAT-SPK2 penetrates the mouse brain after intraperitoneal injection. In a mouse 
tMCAO model, TAT-SPK2 reduced infarct volume and decreased brain water content 
in a dose-dependent manner, while it improved neurological deficit at the highest dose. 
TAT-SPK2 also significantly improved functional recovery and reduced long-term 
brain atrophy of the ischemic hemisphere 30 days after administration. A single dose 
of 80 mg/kg of TAT-SPK2 (20-fold therapeutic dose) or daily 4 mg/kg treatment in 
healthy adult mice for two weeks was well tolerated and showed no overt toxicity. All 
these data suggest that TAT-SPK2 peptide may prove as a candidate of therapeutic agent 
against ischemic stroke.  
During cerebral ischemia/reperfusion, moderate induction of mitophagy is an effective 
strategy to reduce neuronal damage and to improve stroke outcome in ischemic stroke 
(Liu et al., 2013; Shen et al., 2017). PARK2-mediated mitophagy during reperfusion 
can effectively clear damaged mitochondria, which render the brains resistance to 
ischemic injury (Zhang et al., 2013) (Zhang et al., 2014) (Shen et al., 2017). 
Mitochondria are dynamic organelles constantly undergoing fission, fusion, biogenesis 
and selective degradation (Anne Stetler et al., 2013) and interfering with their dynamics 
may have an important effect on cell survival. Silencing or inhibition of DRP1 




vulnerability of neurons to oxygen/glucose deprivation or global ischemia and prevents 
ischemia‐induced mitophagy (Zuo et al., 2016). In the present study, we used 
immunoblotting and immunofluorescence with autophagy/mitophagy markers, and 
electron microscopy to confirm that TAT-SPK2 could induce mitophagy in neurons in 
vivo and in vitro, and that mitophagy is involved in TAT-SPK2-mediated 
neuroprotection against cerebral ischemia. 
Mitophagy is regulated by at least two pathways, including Parkin-dependent 
mitophagy and receptor-mediated mitophagy (Bravo-San Pedro et al., 2017). BNIP3 is 
one of the receptor-related factors that mediates mitophagy (Georgakopoulos et al., 
2017). BNIP3 interacts with LC3 to tether damaged mitochondria to autophagosomes 
through its LC3 interacting region (LIR) motifs towards the cytosol, initiating the 
process of mitophagy (Rikka et al., 2011; Shi et al., 2014). In natural killer cells, BNIP3 
and BNIP3L play essential roles in the clearance of dysfunctional mitochondria and 
mitochondria-associated reactive oxygen species (ROS) to promote cell survival 
(O'Sullivan et al., 2015). BNIP3L knockout mice show impaired mitophagy, larger 
infarct volumes and worse neurological deficit following transient middle cerebral 
artery occlusion (Yuan et al., 2017). The feasibility of inducing cell protection via drug-
induced upregulation of BNIP3-mediated mitophagy was recently documented in a 
study of the effects of mitochonic acid 5 on tumor necrosis factor α-induced apoptosis 
of microglial BV-2 cells (Lei et al., 2018). We have now demonstrated that another 
agent, TAT-SPK2, elicits neuroprotection against ischemia/reperfusion through 
activation of BNIP3-mediated mitophagy.  
Indeed, role of autophagy/mitophagy activation in ischemic stroke is controversial 
(Feng et al., 2017). Basic mitophagy is neuroprotective, whereas excessive mitophagy 
is detrimental (Ashrafi and Schwarz, 2013; Palikaras et al., 2018). Moderate mitophagy 
to clear ischemia/ reperfusion- injured mitochondria may improve mitochondrial 
function such as balance of ROS and ATP generation and inhibition of apoptosis, thus 
helping to protect cerebral ischemia/reperfusion injury (Green et al., 2011; Tang et al., 
2016; Zhang et al., 2013). However, other studies have shown excessive mitophagy 
may exacerbate cerebral ischemic injury. ROS and reactive nitrogen species (RNS) are 
crucial players in activating mitophagy (Nakamura and Lipton, 2020; Xiao et al., 2017). 
Peroxynitrite is a kind of RNS that promotes the recruitment of DRP1 to damaged 




after cerebral ischemia (Feng et al., 2018a). Naringin, a natural antioxidant, can inhibit 
peroxynitrite-mediated mitophagy to protect against ischemia/reperfusion injury (Feng 
et al., 2018b). Therefore, the role of mitophagy in ischemic stroke may be a double-
edged sword. Following factors should be considered in the studies on 
autophagy/mitophagy in ischemic stroke to determine whether autophagy/mitophagy is 
beneficial or detrimental: (1) Protocols for administration of autophagy regulators 
including administration time points, routes and doses, etc.; (2) Specificity of 
autophagy regulators; (3) Animal models of cerebral ischemia with or without 
reperfusion (Feng et al., 2017). To support the induction of mitophagy would be benefit 
for ischemic brains in the study, we thus investigated mitochondrial function after TAT-
SPK2 administration. ATP levels and mitochondrial membrane potential decreased 
significantly in neurons undergoing ischemia/reperfusion, which can be restored by 
TAT-SPK2. However, knockdown of BNIP3 eliminated the protective effect of TAT-
SPK2 on mitochondrial function, suggesting that TAT-SPK2 -induced mitophagy via 
BNIP3 may help to restore mitochondrial function, thereby preventing 
ischemia/reperfusion injury. 
Our previous results demonstrated that SPK2 directly interacts with Bcl-2 through its 
putative BH3 domain, and competes with Beclin1 in Beclin1/ Bcl-2 complex to activate 
autophagy (Sheng et al., 2014b; Song et al., 2017). We thus hypothesized that a TAT-
SPK2 peptide designed based on the BH3 domain of SPK2 would also interact with 
Bcl-2 to break the Beclin-1/Bcl-2 complex. As expected, TAT-SPK2 
immunoprecipitated with endogenous Bcl-2 and decreased the co-immunoprecipitation 
of Beclin1 and Bcl-2. BNIP3 is known to heterodimerize with Bcl-2 through its BH3 
domain (Bellot et al., 2009). Interestingly, TAT-SPK2 but not TAT-L219A, also reduced 
the co-immunoprecipitation between Bcl-2 and BNIP3. These data suggest that TAT-
SPK2 may directly bind to Bcl-2 and disrupt the Bcl-2/BNIP3 complex to activate 
mitophagy.  
Although this study indicates that TAT-SPK2 protects neurons against ischemia/ 
reperfusion injury by activating BNIP3-mediated mitophagy, it should be noted that 
there are still some limitations in this work. First, although we have shown that Mdivi-
1 partially abolished the neuroprotection of TAT-SPK2 in cerebral ischemia via 
inhibition of mitophagy, we did not study the effect of Mdivi-1 on its own on cerebral 
ischemia. Nevertheless, it is worth noting that some studies have shown that Mdivi-1 




et al., 2018a), suggesting that Mdivi-1 does not have a detrimental effect on ischemic 
brains. Moreover, the pharmacokinetics parameters (e.g., half-life or plasma clearance 
of TAT-SPK2) have not been explored in the study. Another potential issue with this 
study is the high mortality in long term study following tMCAO, which decreased the 
statistical power of the study, and might have led to the selection of mice with less 
severe ischemia-reperfusion injury or those affected by an undefined pro-survival 
factor. Although TAT-SPK2 did seem to improve the survival rate of tMCAO mice, this 
effect did not reach statistical significance (data not shown), possibly because the 
peptide was administered only once in long term study. The effect of multiple 
administration of TAT-SPK2 on the long-term survival curve and neurological function 
of tMCAO mice needs further investigation. Furthermore, our data showed that TAT-
SPK2 induced significant neuroprotection when administered up to 3 h after 
reperfusion. Its treatment window might be comparable to that of rtPA (4.5h after 
reperfusion) (Demaerschalk et al., 2016). For future clinical application, whether there 
is an interaction between rtPA and TAT-SPK2 and whether TAT-SPK2 enhances the 
therapeutic effect of rtPA or alleviates the hemorrhagic transformation of rtPA will be 
the research direction for further investigation in the follow-up research. 
In summary, the present study demonstrated that TAT-SPK2 peptide could directly 
bind to Bcl-2 and disrupt the Beclin-1/ Bcl-2 complex and BNIP3/ Bcl-2 complex to 
induce mitophagy. Thus TAT-SPK2 may protect neurons against ischemia/reperfusion 
injury by activating BNIP3-mediated mitophagy. TAT-SPK2 peptide may become a 
potential candidate for the treatment of ischemic stroke.  
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Figure 1. TAT-SPK2 peptide reduced ischemic injury in a mouse model of 
transient focal cerebral ischemia. Mice were subjected to transient middle cerebral 
artery occlusion (tMCAO) for 2 h. TAT-SPK2 peptide (1, 2, and 4 mg/kg), TAT-L219A 
peptide (4 mg/kg) and edaravone (3 mg/kg) was administered intraperitoneally 1 h 
before the onset of ischemia respectively. (A) The infarct volume was detected with 
TTC staining 24 h after reperfusion. The quantitative analysis showed that TAT-SPK2 
decreased ischemia/reperfusion-induced infarction. The neurological deficit (B) and 
water content (C) was also examined at 24 h after reperfusion. n=9-12 animals in each 
group. The neurological deficit scores are shown as median while other data are shown 
as mean ± SD. * P<0.05, ** P< 0.01, *** P<0.001 compared with the vehicle group. 
 
Figure 2. The therapeutic window of the neuroprotection of TAT-SPK2 peptide on 
tMCAO-induced ischemic injury. Mice were subjected to tMCAO for 2 h and were 
intraperitoneally administered with TAT-SPK2 peptide (4 mg/kg) at 0, 1, 2, 3, and 4 h 
after reperfusion. The effects of TAT-SPK2 peptide on infarct volume (A), neurological 
deficit (B) and water content (C) were detected at 24 h after reperfusion. n=8-11 animals 
in each group. The neurological deficit scores are shown as median while other data are 




Figure 3. Long-term effects of TAT-SPK2 on brain atrophy and functional 
recovery in tMCAO mice. Mice were subjected to tMCAO for 2 h and were 
intraperitoneally administered with TAT-SPK2 (4 mg/kg) at the onset of reperfusion. 
Mice were kept for 14 and 28 post-stroke days and then behavior tests were performed. 
(A) Representative images and quantification showed that TAT-SPK2 reduced brain 
shrinkage of the ischemic hemisphere (right) 30 days after tMCAO. (B-C) Effects of 
TAT-SPK2 on the beam balance (B) and rotarod test(C). n=6 animals in each group. 





Figure 4. Daily TAT-SPK2 treatment displayed no overt toxicity in mice. Mice were 
treated with either vehicle or TAT-SPK2 (4 mg/kg/day, intraperitoneal injection) for 2 
weeks. The effects of TAT-SPK2 on body (A), liver (B), spleen (C) and kidney (D) 
weights were assessed. Some representative objective blood biomarkers of organs 
toxicity were tested including creatinine (E) for kidney, glutamic pyruvic transaminase 
(GPT, alanine aminotransferase, ALT) (F) and glutamic oxalacetic transaminase (GOT, 
aspartate aminotransferase, AST) (G) for liver, and lactate dehydrogenase 1 (LDH1) for 
heart (H). (I) Organs including liver, spleen, kidney, testis, heart and lung were 
dissected and stained with haematoxylin and eosin. Representative images are shown. 
Scale bar = 50 μm. n=6 mice in each group. Data are shown as mean ± SD. 
 
Figure 5. TAT-SPK2 induced mitophagy in vivo and in vitro. Mice were treated with 
TAT-SPK2 or TAT-L219A (4 mg/kg, intraperitoneally). Cortex was dissected 1, 3, 6, 
12, and 24 h after administration. The levels of LC3 (A) and P62 (B) and BNIP3 (C) 
were determined with Western blotting. β-actin levels were used as loading control. n=6 
mice in each group. T-L: TAT-L219A; T-S: TAT-SPK2. (D) Electron microscopic 
images show increased number of double-membrane vacuolar structure containing 
mitochondria and partially degraded mitochondria in the TAT-SPK2-treated group. 
Scale bar = 1 μm. N: nucleus. Arrows indicate autophagosomes with engulfed 
mitochondria or mitochondria being wrapped by endoplasmic reticulum, which are 
enlarged in the rightmost insets. (E) DRP1, P62 and Parkin in cytosolic and 
mitochondrial fractions of cortex from mice treated with TAT-SPK2 or TAT-L219A (4 
mg/kg, intraperitoneal). Cyto: cytosolic fraction; Mito: mitochondrial fraction. Tom20 
is a mitochondrial marker amd α-tubulin is a cytosolic marker. n=6 mice in each group. 
(F) TAT-SPK2 increased the colocalization of LC3 and COXIV in HT22 cells. HT22 
cells were treated with 10 μM TAT-SPK2 or TAT-L219A for 1 h. The rightmost column 
shows enlarged cells taken from the boxed area. Scale bar=10 μm. n=3 independent 
experiments. The histogram represents the Manders overlap coefficient of LC3 and 
COXIV in HT22 cells. Data ware shown as mean ± SD. * P<0.05, ** P< 0.01, *** 





Figure 6. Inhibition of mitophagy with Mdivi-1 blocked the neuroprotection of 
TAT-SPK2 peptide in vitro and in vivo. (A) HT22 cells were treated with TAT-SPK2 
or TAT-L219A peptide at 10 μM for 1h, and then were subjected to 6 h of oxygen 
glucose deprivation (OGD). Cells were treated with Mdivi-1 (25 μM) immediately after 
reperfusion. The cell viability was assessed by cell counting kit-8 assay. n=3 
independent experiments. (B-D) Mice were administered with 4 mg/kg TAT-SPK2 
peptide 1 h before ischemia, and then subjected to tMCAO for 2 h. Mdivi-1 (8.5 μM/kg, 
intraperitoneally) was applied at the onset of reperfusion. The infarct volume and 
neurological deficit was detected at 24 h after reperfusion. n=9-13 animals in each 
group. The neurological deficit scores were presented as median while other data were 
presented as mean ± SD. * P<0.05, ** P< 0.01, *** P<0.001. 
 
Figure 7. BNIP3 was involved in the neuroprotection conferred by TAT-SPK2 
peptide. (A) TAT-SPK2 but not TAT-L219A upregulated BNIP3 in vitro. HT22 cells 
were treated with 10 μM TAT-SPK2 or TAT-L219A peptide for indicated time. Then the 
cells were harvested and subjected to Western blot analysis. β-actin levels were used as 
loading control. (B) HT22 cells were transfected with BNIP3 siRNA using 
lipofectamine 2000. BNIP3 was measured with Western blotting. NC: negative control. 
(C) BNIP3 knockdown abolished TAT-SPK2 peptide-induced mitophagy activation. 
Cells were treated with 10 μM TAT-SPK2 for 1 h. Rightmost insets show enlarged cells 
taken from the boxed area. Scale bar=10 μm. The histogram represents the Manders 
overlap coefficient of LC3 and COXIV in HT22 cells. (D) BNIP3 knockdown abolished 
TAT-SPK2-induced protection. 72 h after transfection, cells were treated with TAT-
SPK2 or TAT-L219A at the indicated concentration for 1 h, and then exposed to 
OGD/reperfusion. The cell viability was assessed by cell counting kit-8 assay. (E-F) 
BNIP3 knockdown canceled the protective effect of TAT-SPK2 peptide on 
mitochondrial function represented by ATP levels (E) and TMRM fluorescence (F) in 
HT22 cells. Scale bar=100 μm. n=3 independent experiments. Data were presented as 





Figure 8. TAT-SPK2 peptide interacted with Bcl-2 and disrupted Beclin-1/Bcl-2 or 
BNIP3/Bcl-2 complex. (A) HT22 cells were treated with biotin-labeled peptides (10 
μM, 1 h) and proteins bound to peptides were analyzed with Western blotting with anti-
Bcl-2 antibody. (B-C) TAT-SPK2 reduced co-immunoprecipitation of Beclin1/Bcl-2. 
(D-E) TAT-SPK2 reduced co-immunoprecipitation of BNIP3/Bcl-2. HT22 cell lysates 
derived from vehicle- treated, TAT-L219A- treated or TAT-SPK2- treated cells were 
immunoprecipitated with anti-Bcl-2, separated by SDS-PAGE and subjected to Western 
blot analysis with the indicated antibody. β-actin levels were used as loading control. 
B-T-L: Biotin-TAT-L219A; B-T-S: Biotin-TAT-SPK2. n=3 independent experiments. 












Supplemental methods  
Evaluation of neurological score, infarct volume and brain water content  
Twenty-four hours after reperfusion, the neurological scores were measured by an 
investigator blinded to the experimental grouping, using the following scale (Zhou et 
al., 2016): Grade 0, no neurological deficit; Grade 1, failure to fully extend forelimbs 
when the tail was lifted; Grade 2, circling to the contralateral side; Grade 3, leaning to 
one side; Grade 4, no spontaneous walking, loss of consciousness. After scoring, the 
mice were euthanized by decapitation under anesthesia. Brains were quickly removed, 
cut into five 2mm slices and incubated in 1% 2,3,5-triphenyltetrazolium chloride 
(TTC, Sinopharm Chemical Reagent, China) at 37 °C for 15 min. The infarct volume 
was calculated using the formula: infarct volume = (red area of contralateral side – red 
area of ipsilateral side) / whole contralateral hemisphere area ×100% (Sheng et al., 
2011). The brain slices were then dried at 105°C for 48 h until the wet weight did not 
change. The water content was calculated using the formula: water content = (wet 
weight - dried weight) / wet weight × 100% (Huang et al., 2018; Li et al., 2016). 
Behavioral tests  
A series of behavioral tests including beam balance test and rotarod test was 
conducted in a separate cohort of mice at fourteen and twenty-eight days after 
cerebral ischemia by two investigators blinded to the experimental grouping (Huang 
et al., 2018) (Li et al., 2016).  
Beam balance test  
The beam balance test was used to assess the balance function and motor integration. 
Mice were placed on a 91-cm-long and 3.5-cm-wide beam placed 57 cm above a 
tabletop (Li et al., 2016). Mice were trained 1 day before experiment. The time to 
cross the beam was recorded and the times for 3 successful runs were averaged. 
Rotarod test  
The rotarod test was used to assess the motor coordination of mice. A day before 
experiment, mice were put on a rotarod cylinder with a fixed speed of 12 rpm for 
training. During the next day’s test, the rotarod cylinder was set to accelerate from 12 
to 40 rpm within 300s. The maximum latency time of each mouse to fall from the 
rotarod cylinder was recorded. Each mouse was tested three times. 
In vivo peptide distribution 
Mice were killed at 6h after administration of 4 mg/kg biotin-TAT-SPK2 or 
biotin-SPK2. Brains were perfused with PBS, fixed in 4% paraformaldehyde, 
cryopreserved with 20% and 30% sucrose at 4°C, and kept frozen at -20°C overnight. 
Brains were cut into 20-μm-thick sections with a cryostat. Sections were blocked in 
5% BSA, 0.4% Triton X-100 for 1h, and then incubated with Alexa Fluor 
488-conjugated streptavidin (1:500; Vector Laboratories BA-2000) for 1 h (Liu et al., 
2013b). Fluorescence images were captured using a laser confocal microscope 
(ZEISS LSM710).  
Toxicology assessment 
In the acute toxicity study, normal mice were administered intraperitoneally with a 
single dose of 80 mg/kg TAT-SPK2 (20 times the highest therapeutic dose) or 
TAT-L219A (6 mice per group). Mice were monitored for body weight, food and 
water intake, breathing, excretion and behavior 3 times within 24 hours after 
administration, and once a day thereafter for another 6 days. In the subacute toxicity 
study, normal mice received vehicle or TAT-SPK2 (4 mg/kg/day, intraperitoneal 
injection) for 2 weeks (6 mice per group). Mice were observed daily for weight, food 
and water intake, breathing, excretion and behavior during the administration. 
On the last day of toxicity assessment, the blood of the mice was collected under 
anesthesia. The blood was placed at room temperature for 2 h, and was centrifuged at 
3000 rpm for 20 min at 4°C to obtain serum. The creatinine, glutamic pyruvic 
transaminase (GPT, alanine aminotransferase, ALT), glutamic oxalacetic 
transaminase (GOT, aspartate aminotransferase, AST) and lactate dehydrogenase 1 
(LDH1) in serum were analyzed. The mice were sacrificed under anesthesia, and the 
organs including heart, lung liver, kidney, spleen and testis were removed. The 
samples stored in 10% buffered formalin were dehydrated through a series of graded 
alcohols, embedded in paraffin, sliced into 5 µm thick sections and stained with 
hematoxylin-eosin for pathological examination (Shen et al., 2015). 
  
 
Figure S1. Experimental design of in vivo (A) and in vitro studies (B). (A) The in 
vivo studies sought to examine the effects of TAT-SPK2 on ischemia reperfusion 
injury and BNIP3-mediated mitophagy in a mouse tMCAO model. In the short term 
study, we performed peptide entry assay, efficacy, time window and mitophagy assay. 
In long term study, we investigated the effect of TAT-SPK2 on ischemic atrophy and 
long-term functional recovery. Finally, we evaluated the preliminary toxicity of 
TAT-SPK2. (B) In vitro studies were aimed at exploring the role and mechanism of 
BNIP3-mediated mitophagy in the neuroprotection of TAT-SPK2, and included 
mitophagy assay and protein interaction between BNIP3/Beclin1 and Bcl-2. 
 
Figure S2. Intracellular staining of biotin-Tat-SPK2 peptide in the brain. 
Six hours after treatment with Biotin-Tat-SPK2 or Biotin-SPK2 peptide (4 mg/kg, 
intraperitoneally) , mice were perfused with PBS, fixed in 4% paraformaldehyde, and 
dehydrated with 20% and 30% sucrose. After frozen overnight, the brain was cut into 
20-μm-thick sections and processed for immunofluorescence. Biotin was detected by 












Figure S3. Preliminary toxicological evaluation of TAT-SPK2 in mice. Normal 
mice were administered intraperitoneally with a single dose of 80 mg/ kg of 
TAT-SPK2 (20 times the highest therapeutic dose) or TAT-L219A. (A) The effects of 
TAT-SPK2 on body weights were assessed. Some representative objective blood 
biomarkers of organs toxicity were tested including creatinine (E) for kidney, 
glutamic pyruvic transaminase (GPT, alanine aminotransferase, ALT) (F) and 
glutamic oxalacetic transaminase (GOT, aspartate aminotransferase, AST) (G) for 
liver, and lactate dehydrogenase 1 (LDH1) for heart (H). Organs including liver, 
spleen, kidney, testis, heart and lung were dissected and stained with haematoxylin 
and eosin. Representative images are shown. Scale bar = 50 μm. n=6 mice in each 








Figure S4. Tat-SPK2 peptide upregulates LC3II and downregulates P62 in the 
hippocampus and striatum of mice. Mice were treated with Tat-SPK2 peptide or 
Tat-L219A (4mg/kg, intraperitoneally). Hippocampus and striatum were dissected at 
1, 3, 6, 12, and 24h after administration. The levels of LC3 (A) and P62 (B) were 
determined by Western blotting. β-actin levels were used as loading control. n=6 
mice. Data are shown as mean ± SD. * P<0.05, ** P< 0.01, *** P<0.001 compared 
with the control group. 
 
Figure S5. Tat-SPK2 peptide upregulates BNIP3 in the hippocampus and 
striatum of mice. Mice were treated with Tat-SPK2 peptide or Tat-L219A (4mg/kg, 
intraperitoneally). Hippocampus and striatum were dissected at 1, 3, 6, 12, and 24h 
after administration. BNIP3 level was determined by Western blotting. β-actin levels 
were used as loading control. n=6 mice. * P<0.05, ** P< 0.01, *** P<0.001 compared 





























(during surgery or within 24-hour 
unless noted otherwise) 
Technical failure 
(blood flow not reduced by 90% during 
MCAO or not recovered to 85-95% of 
baseline during reperfusion) 
 
Vehicle 14 3 1 10 
Eda 13 1 3 9 
TAT-L219A 13 2 0 11 
TAT-SPK2 1mg/kg 13 1 0 12 
TAT-SPK2 2mg/kg 13 1 1 11 
TAT-SPK2 4mg/kg 13 0 2 11 
 
Vehicle 12 1 2 9 
TAT-SPK2 0h 12 0 4 8 
TAT-SPK2 1h 13 2 0 11 
TAT-SPK2 2h 12 1 2 9 
TAT-SPK2 3h 12 0 2 10 
TAT-SPK2 4h 12 2 0 10 
 
tMCAO+Vehicle 38 1-24h; 20-1 week; 8-2 week 3 6 
tMCAO+TAT-SPK2 26 2-24h; 10-1 week; 6-2 week 2 6 
 
tMCAO 12 0 3 9 
tMCAO+TAT-SPK2+Vehicle 12 1 1 10 
tMCAO+TAT-SPK2+Mdivi-1 14 1 0 13 
 
